Nuritas Announces Formation of Scientific Advisory Board
DUBLIN, Ireland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Nuritas, a biotechnology company discovering life-changing drugs through the power of artificial intelligence (AI) based peptide discovery, today announced the formation of its scientific advisory board (SAB) with four key appointments: Justin Siegel, Ph.D., David Chernoff, M.D., J Bruce German, Ph.D. and Luke O’Neill, Ph.D.
“We are delighted to have attracted some of the world’s leading experts in drug discovery, metabolism, immunology, food for health, proteomics and molecular diagnostics to support Nuritas as we advance our AI platform and bioactive peptide discovery to address the world’s growing healthcare needs,” said Emmet Browne, chief executive officer of Nuritas. “The formation of our SAB serves to further strengthen Nuritas’s unique approach to discover peptide-based therapies with unmatched speed and accuracy.”
Dr. Nora Khaldi, Ph.D., founder and chief scientific officer of Nuritas said, “The scientific guidance of this group of experts will be key as we accelerate and develop our unique peptide discoveries to improve human health. We are continuing to expand our scientific teams at Nuritas and the addition of the SAB further strengthens this.”
Justin Siegel, Ph.D., is an associate professor of chemistry, biochemistry and molecular medicine in the Genome Center at University of California, Davis. Dr. Siegel combines computational and experimental tools to design and discover enzymes for a wide range of applications including the treatment of human disease, the production of fuels and chemicals and the application of discovered enzymes within food systems to promote health and sustainability. As the faculty director of the Innovation Institute for Food and Health (IIFH), he has accelerated the institute’s innovation cycle and deployment of products and processes that enable safe, sustainable and secure nutrition for all. Dr. Siegel received his Ph.D. in biomolecular structure and design from the University of Washington and has a wealth of experience in translational research, having founded four companies, and currently serves as the director of business development for the Rosetta Commons.
David Chernoff, M.D., is the chief medical officer of SetPoint Medical, a clinical-stage biomedical technology company developing bioelectronic therapy for chronic inflammatory disease. He has 25 years of molecular diagnostics and biopharmaceutical experience and has served as a translational medicine consultant for more than 40 biotechnology, pharmaceutical and medical device companies, and as chief medical officer for a number of companies including Crescendo Bioscience, Adamas Pharma, Tethys Biosciences and Aquinox Pharma. He served as vice president of corporate technology at Elan Pharmaceuticals and medical director at Chiron Diagnostics where he played a pivotal role in the development of viral load assays for HIV, HCV, HBV and CMV. He was a principal with life sciences management consulting firm Keelin Reeds Ventures and entrepreneur in residence and operating partner at TPG Biotech VC Fund. Dr. Chernoff received his M.D. from New York University and completed his medical training and research in internal medicine, rheumatology and infectious disease at UCSF Medical Center.
J Bruce German, Ph.D., is food science and technology director at the Foods for Health Institute at the University of California, Davis and the co-founder of Evolve Biosystems. With the goal of improving human health through diet, Dr. German is studying the structure and function of dietary lipids, the evolution of lactation and the role of milk components in food and health. Dr. German is conducting research studies on the use of metabolic assessments to personalize diet and health, and to better understand the molecular basis for differences in human metabolism and the response to chemical composition and structural organization of foods. He received his Ph.D. from Cornell University and has published more than 400 papers on milk, lipids and food, metabolism and metabolite measurements and food functions and holds numerous patents for technologies and applications of bioactive agents.
Luke O’Neill, Ph.D., is the chair of biochemistry at Trinity College Dublin where he leads the Inflammation Research Group. Dr. O’Neill studies the molecular basis of inflammation with a focus on innate immunity, toll-like receptors, inflammasomes and metabolic reprogramming in macrophage activation and has co-founded three companies, each developing new treatments for inflammatory diseases. Dr. O’Neill was recognized by Clarivates/Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in the field of immunology and has won numerous awards for his research including the European Federation of Immunology Societies medal, the International Cytokine and Interferon Society Milstein Award, The Royal Dublin Society Boyle Medal for Scientific Excellence and The Royal Irish Academy Gold Medal for Life Sciences. Dr. O’Neill received his Ph.D. in pharmacology from the University of London, carried out post-doctoral research at Cambridge U.K., and was elected a Fellow of the Royal Society in 2016.
Founded in 2014, Nuritas is solving the unmet medical needs of the world with the unparalleled capability to develop preventative and curative peptide-based treatments for disease with industry leading speed and accuracy. It is successfully doing so currently in collaboration with a number of industry leading multinationals. The company is changing the landscape of drug discovery by identifying novel peptides using a proprietary artificial intelligence (AI) platform, with in silico predictions validated by their in-house multidisciplinary team of scientists and laboratory. Nuritas engages in collaborative partnerships in the pharmaceutical and consumer goods industries to conduct peptide discovery that is faster, more accurate, and less expensive than traditional drug discovery.
Nuritas has received global recognition for the impact of its innovative technology which includes winning the overall Innovation Award at the Forbes Reinventing America Summit in 2015, the Nutrition Capital Network Venture competition in October 2016 and support from EU Horizon 2020 in 2016 for a peptide that carries the potential to prevent pre-diabetic patients from developing diabetes.
Allison Blum, Ph.D.
LifeSci Public Relations
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Ondot Announces Investment from Citi Ventures to Power Enriched Transactions22.10.2018 17:00 | Pressemelding
The investment will fuel Ondot’s international growth and give cardholders accessing info via Ondot’s platform increased control over and visibility into each transaction Santa Clara, Ca, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the global leader in mobile payments services, today announced that it has secured a strategic funding investment from Citi Ventures. Ondot works directly with financial institutions to give consumers increased control over and visibility into their personal payment transactions. With Ondot, consumers can manage functions such as fraud alerts, transaction limits and purchase location restrictions, all from the convenience of an app on their smartphone or desktop. This investment will further support Ondot’s efforts to grow its international presence and product offerings. Today’s digitally connected consumers are looking for more ways to access detailed information about their digital lives — including personal payment transactions. Ondot’s platform add
Paysafe’s Differentiated Solutions and Customer Service Recognized by Independent Research Firm22.10.2018 15:00 | Pressemelding
Recently Published Report Also Acknowledges its Bold Strategy and Vision LONDON, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Paysafe Group (“Paysafe”), a leading global payments provider, has been named a ‘Strong Performer’ in a recently published third party report: The Forrester Wave™: Global Merchant Payment Providers, Q4 2018. In the report, Forrester acknowledges Paysafe’s bold strategy and vision and gives it the highest possible score in the omnichannel solution criterion. It also describes Paysafe as a “best fit for merchants that are positioned to take advantage of its many value-added services and consumer businesses” and states that the Paysafe product offering “is one of the most differentiated solution value propositions” of any provider in the report. The Forrester report also comments on Paysafe’s customer service focus, stating client references “were extremely pleased with Paysafe’s transparency and customer service.” Joel Leonoff, President and CEO, Paysafe Group, commented: “W
Auth0 Supports Global Growth with Office Expansions in US and UK22.10.2018 15:00 | Pressemelding
New offices accommodate rapid employee growth and reinforce customer commitment BELLEVUE, Wash. and LONDON, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), today announced it has moved into larger offices in Bellevue, WA, and London, UK, to accommodate current and future growth. The company’s headquarters in Bellevue has experienced an upsurge in employees over the past year, signalling its continued growth trajectory in the region. Recently named a Gold winner in the Seattle Business Tech Impact awards, along with additional industry recognition as a great place to work, Auth0 is attracting top talent in the area. The new office occupies the entire 6th floor of the U.S. Bank Plaza, located at 10800 NE 8th St. The new London office at 182-194 Union St. is a former Victorian-style warehouse, located in the South Bank district. This opening also launches the new “Auth0 Identity Centre,” a 50-seat event space where the company will host customers
Mitratech Announces TeamConnect Essentials for Mid-Sized Legal Departments22.10.2018 15:00 | Pressemelding
New SaaS Legal Operations Solution Can Save $250,000 Per Year in Staff Time Savings and Reduced Legal Spend AUSTIN, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Mitratech today announced the launch of TeamConnect Essentials, an easy-to-use, quick-to-implement SaaS legal operations solution designed for legal departments who want to leverage built-in best practices validated by 30 years of Mitratech’s client experience. Essentials is built on Mitratech’s TeamConnect platform and acts as a central hub for all legal operations, including integrated matter management, outside counsel management, e-Billing, Microsoft® Office integration, and reporting, delivered as an adaptable, cloud-based solution. “Thirty percent of FORTUNE 500 companies currently use TeamConnect as a platform for legal department innovation. We’ve taken our experience with those customers and others, coupled it with a streamlined implementation program, and created a unique solution for legal departments earlier in their tr
Bombardier Transportation confirms Bangkok Mass Transit System Public Co. Ltd. (BTSC) as the previously undisclosed customer for 20-year maintenance services contract in South-East Asia22.10.2018 14:00 | Pressemelding
This long-term maintenance services contract for its INNOVIA monorail 300 system, continues Bombardier’s growth story in services Bangkok’s first monorail lines will transport over 400,000 passengers daily BERLIN, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/a9519948-e13b-4941-a2e7-7e088530f92f Mobility technology leader Bombardier Transportation announced today that Bangkok Mass Transit System Public Co. Ltd. (BTSC) is the previously undisclosed customer that signed a contract for 20 years of maintenance services. The services will be provided for the BOMBARDIER INNOVIA monorail 300 systems in delivery for Thailand’s first two monorail lines: the Bangkok pink and yellow lines. The order was announced by Bombardier on July 6, 2018 and is valued at approximately 245 million euro ($287 million US). Commenting on the order, Khun Keeree Kanjanapas,
Spartan Essential Turn-Key Design Significantly Reduces Time-to-Market for Equipment Manufacturers22.10.2018 14:00 | Pressemelding
Compact Design with Exceptional Wi-Fi Performance SAN JOSE, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ: QTNA), the innovator and global leader of high-performance Wi-Fi solutions, has introduced Spartan Essential, a fast to market turn-key design to address multiple consumer Wi-Fi applications such as mesh, access point for wired extenders and simple boosters for upgrading existing gateway wireless LANs. This new compact product eliminates the need for lengthy feature developments, testing and qualification by Original Equipment Manufacturers (OEMs), Original Design Manufacturers (ODMs) and software integrators. Spartan Essential is a complete turn-key design that uses Quantenna’s award-winning QSR1000 Wave 2 chipset solution and supports dual-band dual-concurrent 4x4 802.11ac and 2x2 802.11n. The Spartan Essential design offers the following advantages: Compact and aesthetic industrial design High-performance internal antennas Single PCB design fo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom